Most Read Articles
Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.
26 Jul 2019
Supplementation with specific micronutrients results in a significant reduction in the frequency and severity of adverse effects during oral contraception treatment, a study has shown.
Pearl Toh, 18 Aug 2017
The traditional medicinal herbs ginseng, dong-quai, and turmeric do not appear to affect platelet aggregation and increase bleeding risk when used alone or together with aspirin, despite the belief that these herbs have “blood-activating” properties in traditional medicine theory, a recent study shows.
Roshini Claire Anthony, 6 days ago

Adding veliparib to a carboplatin-paclitaxel combination improved progression-free survival (PFS) in patients with BRCA1/2 hormone receptor-positive (HR+) or triple-negative breast cancer (TNBC), subgroup analysis of the phase III BROCADE3* trial showed.

Peptic Ulcer (Patient Counselling Guide)

05 Jun 2020
Peptic ulcers are holes or breaks in the lining of the stomach or the duodenum (the upper part of the small intestine), areas that come into contact with stomach acids (hydrochloric acid) and enzymes (pepsin). In order to avoid mucosal damage and digestion of the stomach itself, the normal stomach also secretes a protective alkaline mucus. The balance between potentially damaging and protective factors can be disrupted in various conditions, resulting in inflammation of the stomach or gastritis. More severe mucosal damage can occur, leading to development of an ulcer (complete loss of the mucosa) or erosion (loss of part of the thickness of the mucosa). The underlying causes of peptic ulceration are diverse. Agents such as alcohol and drugs (eg, NSAIDs, steroids, anticoagulants, selective serotonin reuptake inhibitors, alendronate, risedronate) can lead to mucosal damage. Infection with the bacterium Helicobacter pylori (H. pylori) is another cause. Other risk factors include cigarette smoking, alcohol abuse, psychological stress and genetics. Having a family member with peptic ulcer may make a person more likely to develop peptic ulcer. Some peptic ulcers may heal without treatment. However, the symptoms may recur and worsen if the cause of the ulcer is not eliminated. If not properly treated, ulcers can lead to serious health problems including bleeding, perforation (a hole through the wall of the stomach) or gastric outlet obstruction from swelling or scarring that blocks the passageway leading from the stomach to the small intestine.

* Click below to view the Patient Counselling Guide in Thai

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.
26 Jul 2019
Supplementation with specific micronutrients results in a significant reduction in the frequency and severity of adverse effects during oral contraception treatment, a study has shown.
Pearl Toh, 18 Aug 2017
The traditional medicinal herbs ginseng, dong-quai, and turmeric do not appear to affect platelet aggregation and increase bleeding risk when used alone or together with aspirin, despite the belief that these herbs have “blood-activating” properties in traditional medicine theory, a recent study shows.
Roshini Claire Anthony, 6 days ago

Adding veliparib to a carboplatin-paclitaxel combination improved progression-free survival (PFS) in patients with BRCA1/2 hormone receptor-positive (HR+) or triple-negative breast cancer (TNBC), subgroup analysis of the phase III BROCADE3* trial showed.